biostudies-literatureHeo STNational Institutes of Health and Astellas PharmaPfizer, IncJohn S. Dunn FoundationInstitutional CoreNIAID NIH HHSNCI NIH HHSNational Institutes of HealthMD Anderson Cancer Center216-225https://www.ebi.ac.uk/biostudies/studies/S-EPMC5850538biostudies-literatureUnknown65(2)<h4>Background</h4>Azole-resistant aspergillosis in high-risk patients with hematological malignancy or hematopoietic stem cell transplantation (HSCT) is a cause of concern.<h4>Methods</h4>We examined changes over time in triazole minimum inhibitory concentrations (MICs) of 290 sequential Aspergillus isolates recovered from respiratory sources during 1999-2002 (before introduction of the Aspergillus-potent triazoles voriconazole and posaconazole) and 2003-2015 at MD Anderson Cancer Center. We also tested for polymorphisms in ergosterol biosynthetic genes (cyp51A, erg3C, erg1) in the 37 Aspergillus fumigatus isolates isolated from both periods that had non-wild-type (WT) MICs. For the 107 patients with hematologic cancer and/or HSCT with invasive pulmonary aspergillosis, we correlated in viClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaChanges in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015.PMC5850538CA16672R01 CA180279R01 AI109025AI109025Mikos AGVerweij PETarrand JTverdek FMeis JFHeo STJiang YLewis REAlbert NDTatara AMKontoyiannis DPPerlin DSJimenez-Ortigosa CfalseChanges in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015.<h4>Background</h4>Azole-resistant aspergillosis in high-risk patients with hematological malignancy or hematopoietic stem cell transplantation (HSCT) is a cause of concern.<h4>Methods</h4>We examined changes over time in triazole minimum inhibitory concentrations (MICs) of 290 sequential Aspergillus isolates recovered from respiratory sources during 1999-2002 (before introduction of the Aspergillus-potent triazoles voriconazole and posaconazole) and 2003-2015 at MD Anderson Cancer Center. We also tested for polymorphisms in ergosterol biosynthetic genes (cyp51A, erg3C, erg1) in the 37 Aspergillus fumigatus isolates isolated from both periods that had non-wild-type (WT) MICs. For the 107 patients with hematologic cancer and/or HSCT with invasive pulmonary aspergillosis, we correlated in vi2017-01-01T00:00:00Z2017 Jul2026-05-02T06:58:24.575Z2019-03-26T23:46:21ZS-EPMC58505382837930410.1093/cid/cix297